vs
Esperion Therapeutics, Inc.（ESPR）与UNIVERSAL TECHNICAL INSTITUTE INC（UTI）财务数据对比。点击上方公司名可切换其他公司
UNIVERSAL TECHNICAL INSTITUTE INC的季度营收约是Esperion Therapeutics, Inc.的1.3倍（$221.4M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 6.7%），过去两年UNIVERSAL TECHNICAL INSTITUTE INC的营收复合增速更高（11.7% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
环球技术学院（UTI）是美国的营利性私立技术院校集团，1965年由罗伯特·斯威特创立，专注于提供职业技术类教育课程，培养符合产业需求的技能型人才，在美职业教育领域拥有较长的运营历史与行业经验。
ESPR vs UTI — 直观对比
营收规模更大
UTI
是对方的1.3倍
$168.4M
营收增速更快
ESPR
高出137.0%
6.7%
两年增速更快
UTI
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $221.4M |
| 净利润 | — | $433.0K |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 0.2% |
| 净利率 | — | 0.2% |
| 营收同比 | 143.7% | 6.7% |
| 净利润同比 | — | -60.5% |
| 每股收益（稀释后） | $0.32 | $0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRUTI
| Q1 26 | — | $221.4M | ||
| Q4 25 | $168.4M | $220.8M | ||
| Q3 25 | $87.3M | $222.4M | ||
| Q2 25 | $82.4M | $204.3M | ||
| Q1 25 | $65.0M | $207.4M | ||
| Q4 24 | $69.1M | $201.4M | ||
| Q3 24 | $51.6M | $196.4M | ||
| Q2 24 | $73.8M | $177.5M |
净利润ESPRUTI
| Q1 26 | — | $433.0K | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | $-31.3M | $18.8M | ||
| Q2 25 | $-12.7M | $10.7M | ||
| Q1 25 | $-40.5M | $11.4M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | $-29.5M | $18.8M | ||
| Q2 24 | $-61.9M | $5.0M |
营业利润率ESPRUTI
| Q1 26 | — | 0.2% | ||
| Q4 25 | 50.6% | 7.1% | ||
| Q3 25 | -11.4% | 11.2% | ||
| Q2 25 | 8.6% | 6.9% | ||
| Q1 25 | -34.0% | 8.1% | ||
| Q4 24 | -6.4% | 13.6% | ||
| Q3 24 | -31.0% | 13.3% | ||
| Q2 24 | 3.5% | 4.2% |
净利率ESPRUTI
| Q1 26 | — | 0.2% | ||
| Q4 25 | — | 5.8% | ||
| Q3 25 | -35.9% | 8.4% | ||
| Q2 25 | -15.4% | 5.2% | ||
| Q1 25 | -62.2% | 5.5% | ||
| Q4 24 | — | 11.0% | ||
| Q3 24 | -57.2% | 9.6% | ||
| Q2 24 | -83.9% | 2.8% |
每股收益（稀释后）ESPRUTI
| Q1 26 | — | $0.01 | ||
| Q4 25 | $0.32 | $0.23 | ||
| Q3 25 | $-0.16 | $0.33 | ||
| Q2 25 | $-0.06 | $0.19 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $0.40 | ||
| Q3 24 | $-0.15 | $0.35 | ||
| Q2 24 | $-0.33 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $162.0M |
| 总债务越低越好 | — | $127.8M |
| 股东权益账面价值 | $-302.0M | $339.9M |
| 总资产 | $465.9M | $852.2M |
| 负债/权益比越低杠杆越低 | — | 0.38× |
8季度趋势，按日历期对齐
现金及短期投资ESPRUTI
| Q1 26 | — | $162.0M | ||
| Q4 25 | $167.9M | $162.8M | ||
| Q3 25 | $92.4M | $169.1M | ||
| Q2 25 | $86.1M | $70.7M | ||
| Q1 25 | $114.6M | $96.0M | ||
| Q4 24 | $144.8M | $172.0M | ||
| Q3 24 | $144.7M | $161.9M | ||
| Q2 24 | $189.3M | $115.5M |
总债务ESPRUTI
| Q1 26 | — | $127.8M | ||
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M |
股东权益ESPRUTI
| Q1 26 | — | $339.9M | ||
| Q4 25 | $-302.0M | $335.9M | ||
| Q3 25 | $-451.4M | $328.1M | ||
| Q2 25 | $-433.5M | $306.8M | ||
| Q1 25 | $-426.2M | $293.9M | ||
| Q4 24 | $-388.7M | $280.0M | ||
| Q3 24 | $-370.2M | $260.2M | ||
| Q2 24 | $-344.2M | $239.4M |
总资产ESPRUTI
| Q1 26 | — | $852.2M | ||
| Q4 25 | $465.9M | $834.0M | ||
| Q3 25 | $364.0M | $826.1M | ||
| Q2 25 | $347.1M | $740.8M | ||
| Q1 25 | $324.0M | $720.4M | ||
| Q4 24 | $343.8M | $753.8M | ||
| Q3 24 | $314.1M | $744.6M | ||
| Q2 24 | $352.3M | $706.0M |
负债/权益比ESPRUTI
| Q1 26 | — | 0.38× | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $7.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 16.33× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRUTI
| Q1 26 | — | $7.1M | ||
| Q4 25 | $45.2M | $3.1M | ||
| Q3 25 | $-4.3M | $57.1M | ||
| Q2 25 | $-31.4M | $18.1M | ||
| Q1 25 | $-22.6M | $-789.0K | ||
| Q4 24 | $-35.0M | $23.0M | ||
| Q3 24 | $-35.3M | $67.5M | ||
| Q2 24 | $-7.2M | $10.0M |
自由现金流ESPRUTI
| Q1 26 | — | — | ||
| Q4 25 | — | $-19.2M | ||
| Q3 25 | — | $40.6M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $-35.5M | $60.0M | ||
| Q2 24 | $-7.3M | $3.0M |
自由现金流率ESPRUTI
| Q1 26 | — | — | ||
| Q4 25 | — | -8.7% | ||
| Q3 25 | — | 18.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | -68.7% | 30.6% | ||
| Q2 24 | -9.9% | 1.7% |
资本支出强度ESPRUTI
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 10.1% | ||
| Q3 25 | 0.0% | 7.4% | ||
| Q2 25 | 0.0% | 5.5% | ||
| Q1 25 | 0.0% | 5.3% | ||
| Q4 24 | 0.0% | 1.7% | ||
| Q3 24 | 0.3% | 3.8% | ||
| Q2 24 | 0.1% | 4.0% |
现金转化率ESPRUTI
| Q1 26 | — | 16.33× | ||
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
UTI
暂无分部数据
